title: [A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer].
abstract: A dose-escalation study was conducted for patients with inoperable or recurrent breast cancer in order to determine the recommended dose (RD) of capecitabine combined with a fixed dose of weekly paclitaxel. Capecitabine was administered twice daily from day 1 through day 14 combined with paclitaxel given on days 1 and 8, every 21 days. Dose-limiting toxicities(DLT)were evaluated during the first two cycles. Three patients were recruited at one of two dose levels (capecitabine 1,255 mg/m2 or 1,657 mg/m2, paclitaxel 80 mg/m2). In this study, no DLT was seen in each level, and the RD of capecitabine was determined to be 1,657 mg/m2.
authors.affiliation: Dept. of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine.
authors.forename: Jun
authors.initials: J
authors.lastname: Horiguchi
authors.forename: Yukio
authors.initials: Y
authors.lastname: Koibuchi
authors.forename: Nana
authors.initials: N
authors.lastname: Rokutanda
authors.forename: Rin
authors.initials: R
authors.lastname: Nagaoka
authors.forename: Mami
authors.initials: M
authors.lastname: Kikuchi
authors.forename: Ayako
authors.initials: A
authors.lastname: Sato
authors.forename: Hiroki
authors.initials: H
authors.lastname: Odawara
authors.forename: Yuko
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: Hideaki
authors.initials: H
authors.lastname: Tokiniwa
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Iino
authors.forename: Izumi
authors.initials: I
authors.lastname: Takeyoshi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D017239:Paclitaxel; D005472:Fluorouracil